BioNano Genomics, Inc. (BNGO) Posts Q3 Revenue of $2.8M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Bionano Genomics Releases Operating Results for Third Quarter 2018
November 7, 2018 4:01 PM ESTCompleted recent IPO raising $23.7 million in gross proceeds 23% increase in product revenue for the first nine months of 2018
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced financial results for the three and nine months ended September 30, 2018.
Recent Accomplishments and Business Highlights
Completed an Initial Public Offering in August 2018, raising $23.7 million of gross proceeds (including the... More